The Alexipharmic Drugs Market is estimated to grow from USD xx billion in 2020 to USD xx billion by 2026 at a healthy CAGR of 4.9% during the forecast period.
Alexipharmic drugs is known to work as an antidote and are used to ward off effects of previously administered medications and drug poisoning. It can also be utilized as a defense against several types of microbial infections. They are also used in psychotherapeutic treatment for management of alcohol and drugs of abuse dependence. The primary focus of psychotherapeutic treatment is to enable patients to confront dependence on psychoactive substances including prescription drugs, and illegal drugs such as heroin, cocaine, MDMA, and alcohol.
Covid-19 Impact Analysis
The outbreak of COVID-19 positively influenced the alexipharmic drugs industry. There was a huge brunt on medical field to treat COVID-19 patients, which created a shift towards treating these patients. This resulted in a shift in treating COVID-19 patients, thus boosting the market growth.
Key Players
Key players operating in the global Alexipharmic Drugs Market are-
Bausch Health Companies Inc (Canada)
Ethypharm S. A. (France)
Fresenius SE & Co. KGaA (Fresenius Kabi) (Germany)
Alkermes, Inc. (Ireland)
Mylan N.V. (US)
B. Braun Melsungen AG (Germany)
Emergent BioSolutions (US)
Hikma Pharmaceuticals (UK)
SGPharma Pvt. Ltd. (India)
Merck & Co., Inc. (US)
Market Dynamics
The Alexipharmic Drugs market is mainly driven by surging prevalence of several types of chronic diseases and overdose of prescribed drugs drives the market. In addition, surge in drug abuse worldwide and increase in alcohol consumption, rising R&D activities in pharmaceutical industry, growth in the death rate owing to drug overdoses such as acetaminophen toxicity and cyanide poisoning, further augments the market growth.
Segment’s Analysis
Application Trends
Based on application, the alexipharmic drugs market has been classified into alcoholic overdose, opioid overdose, benzodiazepine overdose, cyanide poisoning, and others. The opioid overdose segment accounted for the largest market share in 2020, owing to strong adoption of opioids as primary line treatment by physicians and higher preference among the patients. Moreover, increasing incidences of deaths owing to illicit consumption of synthetic opioids spurred the demand for these products, further bolsters the segment growth.
Regional Trends
By region, the North America Alexipharmic Drugs market accounted for a significant share of almost 44% in 2020 and is expected to grow at a robust CAGR during the review period. The Alexipharmic Drugs market growth is mainly propelled by high smuggling of drugs and usage of opioids, favorable reimbursement coverage across developed countries, rising investments in healthcare infrastructure, rise in the number of plastic surgery, cancers, diabetic ulcer amputation cases, further proliferates the market growth in the region.
The Asia Pacific Alexipharmic Drugs market is expected to grow at a healthy CAGR during the review on account of growing awareness associated with high alcohol consumption and increasing cases of cancer. Moreover, strong expansion of healthcare infrastructure and supportive government policies, further bolsters the regional market growth.
Critical Questions Answered in the Report
This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global alexipharmic drugs market. The historic years considered for the study are 2016-2019, base year is 2020, estimated year is 2021, and forecast period is 2022-2026. Following are the critical questions answered in the report.
What are the key trends in the global alexipharmic drugs market?
How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in next five years?
What is the impact of COVID-19 on global alexipharmic drugs market?
What are the key strategies adopted by the major vendors to lead in the global alexipharmic drugs market?
The target audience of Alexipharmic Drugs Market includes-
Alexipharmic Drugs Vendors
Alexipharmic Drugs Manufacturers
Alexipharmic Drugs Distributors
Organizations
Government Bodies.
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.
LOADING
LOADING
×
Please enter your contact details. It will allow our analysts to reach out to you.
Key players operating in the global Alexipharmic Drugs Market are- Bausch Health Companies Inc (Canada), Ethypharm S. A. (France), Fresenius SE & Co. KGaA (Fresenius Kabi) (Germany), Alkermes, Inc. (Ireland), Mylan N.V. (US), B. Braun Melsungen AG (Germany), Emergent BioSolutions (US), Hikma Pharmaceuticals (UK), SGPharma Pvt. Ltd. (India), Merck & Co., Inc. (US).
The Alexipharmic Drugs market is mainly driven by surging prevalence of several types of chronic diseases and overdose of prescribed drugs drives the market.
North America Alexipharmic Drugs market accounted for a significant share of almost 44% in 2020 and is expected to grow at a robust CAGR during the review period.
The Global Alexipharmic Drugs Market is estimated to grow from USD xx billion in 2020 to USD xx billion by 2026 at a healthy CAGR of 4.9% during the forecast period.
